Venter teams with Cleveland Clinic on aging; Redx launches immunology offshoot;

@FierceBiotech: Special report: The 25 most influential people in biopharma in 2015. Feature | Follow @FierceBiotech

@JohnCFierce: Circassia snags a pair of asthma biotechs for $376M. Report | Follow @JohnCFierce

@DamianFierce: Wait did they just invent NantPharma for this deal? Is there a geneology chart for the NantFamily? Release | Follow @DamianFierce

> J. Craig Venter's Human Longevity is joining forces with Cleveland Clinic for a human genomics collaboration aimed at disease discovery, a little more than a year after the company kicked off operations with the promise of building the world's biggest human gene-sequencing platform. Story

> Redx Pharma launched its third subsidiary, focused on immunology and promising to deliver up to 8 new drug candidates over the next few years. More

> AbbVie's ($ABBV) blockbuster Humira won FDA approval for use in the hidradenitis suppurativa, a chronic inflammatory skin disease. News

Medical Device News

@FierceMedDev: Swedish asthma diagnostic company Aerocrine to be acquired by biotech Circassia for $214M. Article| Follow @FierceMedDev

@VarunSaxena2: Medtronic's leadless pacemaker and MRI-safe defibrillator present positive trial data at cardiology conference. Article | Follow @VarunSaxena2

@EmilyWFierce: OncoCyte ropes in $7M for cancer diagnostic R&D. FierceDiagnostics story | Follow @EmilyWFierce

> Data presented at cardiology conference show Abbott's MitraClip can cut arrhythmias in half. More

> Medtronic's leadless pacemaker and MRI-safe defibrillator present positive trial data at cardiology conference. Report

Pharma News

@FiercePharma: Japan's MHLW sets Sovaldi price, hep C competition heats up. FiercePharmaAsia article | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing this week: Alexion expanding in Ireland. Will spend $506M on its first biologics plant outside of U.S. Story | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Mylan shareholders face big M&A-related taxes, especially if Teva's bid succeeds. Report | Follow @CarlyHFierce

> Eisai predicts long-awaited operating profit rise for fiscal 2015. Article

> AbbVie nabs FDA's orphan drug tag for Humira in HS. Item

> New CEO Weber deals with Takeda's loss and promises brighter future. Report

Suggested Articles

After beating the standard of care at keeping testosterone levels down, Myovant's prostate cancer drug fell short in patients with metastatic disease.

A Mount Sinai-led team found that immune cells in the brain protect it from abnormal activation that can lead to behavioral problems.

Results from the small cohort suggest the vaccine triggers comparable immune responses in younger and older adults.